Highland Therapeutics Inc. is a specialty pharmaceutical company that, through its wholly owned subsidiary Ironshore Pharmaceuticals & Development, leverages its proprietary DELEXIS® technology to optimize delivery of previously approved drugs. Its lead candidates are HLD-200 (a next‑generation methylphenidate) and HLD-100 (a next‑generation amphetamine) intended for nighttime dosing to provide symptom control immediately upon waking and throughout the day. The company aims to address inadequate morning symptom control in ADHD and is exploring additional indications, including potential use of HLD-100 in Binge Eating Disorder. Highland announced a US$50 million financing that management says will enable a pivot from a pure R&D organization to a scalable pharmaceutical company and support commercialization. Proceeds are earmarked to complete clinical development, secure dedicated manufacturing capacity, build U.S. sales and marketing infrastructure, engage in pre-marketing and medical education activities, and pursue pipeline expansion opportunities. The financing consisted of a US$25 million equity offering and a US$25 million credit facility. Highland Therapeutics is a Toronto-based pharmaceutical company led by President & CEO David Lickrish. Through its wholly owned subsidiary Ironshore Pharmaceuticals & Development, Inc., the company is developing HLD-200 (methylphenidate), which is being investigated in an ongoing Phase III clinical trial called the Clinical Endpoint Evaluation Study (CEES) for treatment of ADHD symptoms. Highland also plans a Phase IIB/III study of HLD-100 (amphetamine). The company closed $25M in funding from an unnamed private equity investor. Proceeds are intended to complete clinical development of HLD-200 through a New Drug Application, support the HLD-100 Phase IIB/III study, expand manufacturing capacity and pursue pipeline expansion opportunities. The article does not disclose additional financial metrics or other participating investors. Highland Therapeutics leverages proprietary technologies to optimize delivery of previously approved drug products. Its two lead compounds, HLD-100 (a novel formulation of amphetamine) and HLD-200 (a novel formulation of methylphenidate), are being developed to address lack of symptom control during the early morning routine in patients with ADHD. The company is led by President and CEO David Lickrish and is supported by an internal Clinical Development group responsible for manufacturing and clinical development of the lead compounds. Highland completed a US$6.7M financing and intends to use the funds to conduct up to five clinical studies across its two candidates. Additional uses of proceeds include market research to refine commercialization strategies, scaling up manufacturing activities, and general corporate purposes.

Total raised

$82M

Funding rounds

4

Latest round

Debt Financing

Latest activity

Jun 2015